Publishing our scientific research and findings.

We are committed to publishing the results from our pre-clinical and clinical research in collaboration with the scientists, physicians, researchers and others with whom we collaborate at medical meetings and in peer-reviewed publications.

Date Type Description Link
Dec 2023 Journal Papers

Hurrish, et. al., Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro. Biochem Pharmacol. 2023 Dec 9:115981.
Dec 2023 Poster

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML)

Apr 2022 Poster

ME-344, a novel isoflavone mitochondrial inhibitor, in combination with venetoclax constitutes a new metabolism-targeted approach to overcome resistance to Bcl-2 inhibition and standard of care treatment in AML, AACR Annual Meeting 2022

Dec 2021 Poster

A Phase 1 Dose-Escalation Study of the Oral CDK Inhibitor Voruciclib in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia (AML): Preliminary Results of the Completed Dose Escalation Stage in AML, 63rd ASH Annual Meeting, December 2021

Dec 2021 Poster

A Novel Isoflavone, ME-344, Enhances Venetoclax Antileukemic Activity Against AML via Suppression of Oxidative Phosphorylation and Purine Biosynthesis, 63rd ASH Annual Meeting, December 2021

Apr 2021 Poster

Voruciclib, a CDK9 inhibitor, downregulates MYC and inhibits proliferation of KRAS mutant cancers in preclinical models, AACR Annual Meeting 2021

Aug 2020 Journal Papers

Zhang, et al. Voltage-Dependent Anion Channels Influence Cytotoxicity of ME-344, a Therapeutic Isoflavone. J Pharmacol Exp Ther. 2020 Aug;374(2):308-318.
Feb 2020 Journal Papers

Luedtke, et al. Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia. Signal Transduct Target Ther. 2020 Feb 26;5(1):17.
Jan 2020 Journal Papers

Quintela-Fandino, et al. Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer. Clin Cancer Res. 2020 Jan 1;26(1):35-45.
Aug 2019 Journal Papers

Zhang, et al. Isoflavone ME-344 Disrupts Redox Homeostasis and Mitochondrial Function by Targeting Heme Oxygenase 1. Cancer Res. 2019 Aug 15;79(16):4072-4085.
Jan 2019 Poster

A randomized phase 0 trial of the mitocondrial inhibitor ME344 or placebo added to the antiangiogenic (Aa) bevacizumab in early HER2-negative breast cancer (E-HERNEBC), ASCO Annual Meeting, June 2019

Jan 2019 Journal Papers

Zhang, et al. Pharmacology of ME-344, a novel cytotoxic isoflavone. Adv Cancer Res. 2019;142:187-207
Dec 2018 Poster

Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced by the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia

Aug 2018 Poster

Abrogation of resistance against bevacizumab (Bev) by mitochondrial inhibition: a phase 0 randomized trial of Bev plus ME344 or placebo in early HER2-negative breast cancer (HERNEBC), ASCO Annual Meeting, June 2018

Dec 2017 Journal Papers

Dey, et al. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. Sci Rep. 2017 Dec 21;7(1):18007.
Jan 2017 Journal Papers

Diamond, et al. Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers. Invest New Drugs. 2017 Oct;35(5):627-633.
Aug 2016 Journal Papers

Jeyaraju, et al. A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia. Oncotarget. 2016 Aug 2;7(31):49777-49785.
Aug 2016 Journal Papers

Manevich, et al. Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344. J Pharmacol Exp Ther. 2016 Aug;358(2):199-208.
Jul 2016 Journal Papers

Eliades, et al. A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. Cancer Biol Ther. 2016 Jul 2;17(7):778-84.
Jun 2016 Journal Papers

Navarro, et al. Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics. Cell Rep. 2016 Jun 21;15(12):2705-18.
Apr 2016 Poster

Voruciclib, a clinical stage CDK inhibitor sensitizes triple negative breast cancer xenografts to proteasome inhibition. AACR Annual Meeting, April 2016

Nov 2015 Journal Papers

Paiva, et al. Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. PLoS One. 2015 Nov 25;10(11)
Jun 2015 Poster

Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma. ASCO Annual Meeting, June 2015

Apr 2015 Poster

ME-344, a Novel Isoflavone with Activity as a Mitochondrial Oxygenase Inhibitor. AACR Annual Meeting, Apr 2015

Apr 2015 Journal Papers

Bendell, et al. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors. Cancer. 2015 Apr 1;121(7):1056-63.
Jan 2015 Journal Papers

Lim, et al. Anti-cancer analogues ME-143 and ME-344 exert toxicity by directly inhibiting mitochondrial NADH: ubiquinone oxidoreductase (Complex I). Am J Cancer Res. 2015 Jan 15;5(2):689-701.
Aug 2011 Journal Papers

Alvero, et al. Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Mol Cancer Ther. 2011 Aug;10(8):1385-93.
Jul 2009 Journal Papers

Alvero, et al. NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway. Cancer. 2009 Jul 15;115(14):3204-16